Report Type: Industry Trends
Report Category: Research Insights
Report Subcategory: Oligonucleotide
Price: 2999.00
Date: July 2021

Oligonucleotides: Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Oligonucleotides:
Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein expression through several distinct mechanisms.

By targeting the source of the pathogenesis, ASO-mediated therapies have a higher chance of success than therapies targeting downstream pathways.

Advances in the understanding of ASO pharmacology have provided momentum for translating these therapeutics into the clinic.

Top & Promising Drugs by Company:    
Novartis AG- Leqvio (inclisiran)
Biogen Inc- Spinraza (nusinersen)
Alnylam Pharmaceuticals Inc- Onpattro (patisiran)
Silence Therapeutics Plc-  (SLN-124)
Alnylam Pharmaceuticals Inc- Givlaari (givosiran)
Akcea Therapeutics Inc- Tegsedi (inotersen sodium)
Nippon Shinyaku Co Ltd- Viltepso (viltolarsen)
Sarepta Therapeutics Inc- Exondys 51 (eteplirsen)
IVERIC bio Inc- Zimura (avacincaptad pegol sodium)
Sarepta Therapeutics Inc- Vyondys 53 (golodirsen)
Sarepta Therapeutics Inc- Amondys 45 (casimersen)
Jazz Pharmaceuticals Plc- Defitelio (defibrotide sodium)